IgG1 heavy chain-coding gene polymorphism (G1m allotypes) and development of antibodies-to-infliximab

Autor: Margaret Goodall, Filip Baert, Hervé Watier, Maja Noman, Severine Vermeire, Marc Ohresser, Charlotte Magdelaine-Beuzelin, Danielle Degenne, Paul Rutgeerts, Maire-Paule Lefranc, Roy Jefferis, Gert Van Assche, Jean-Michel Dugoujon

Publikováno v: Pharmacogenetics and Genomics
Pharmacogenetics and Genomics, Lippincott, Williams & Wilkins, 2009, 19 (5), pp.383-387. ⟨10.1097/FPC.0b013e32832a06bf⟩
Pharmacogenet. Genomics
Pharmacogenet. Genomics, 2009, 19 (5), pp.383-387

International audience; Objective The chimeric anti-tumor necrosis factor-alpha antibody infliximab is known to induce antibodies-to-infliximab (ATI) in some treated patients. Immunogenicity in murine variable domains is expected; however, constant d

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e0f358989f7db50da640b1f1bd369408
https://pubmed.ncbi.nlm.nih.gov/19319024